Investor Relations


Welcome to Trovagene Investor Relations

Corporate Profile

Headquartered in San Diego, California, Trovagene is leveraging its proprietary Precision Cancer Monitoring® (PCM) technology for the detection and monitoring of circulating tumor DNA (ctDNA) in urine and blood. The Company’s technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene’s PCM technology is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally. 

Trovagene Corporate Presentation
September 12, 2016 - September 13, 2016

Trovagene's Chief Scientific Officer, Mark Erlander, Ph.D. will be presenting; Clinical Utility for Detection and Monitoring Circulating Tumor DNA from Urine and Plasma, at the 3rd Precision...

August 10, 2016 - August 12, 2016

Trovagene's Director of Medical and Scientific Affairs, Victoria Raymond, will be presenting at the Precision Medicine Leaders Summit 2016 taking place August 10-12th, 2016 at the Manchester Grand...

August 4, 2016
2:00pm - 3:00pm PDT

Trovagene will report financial results for the second quarter 2016 on Thursday,August 4, 2016 at 5:00 p.m. Eastern Standard Time (2:00 p.m. Pacific Standard Time). Trovagene’s senior management...
print email